Results 61 to 69 of about 154,062 (69)

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

Oncogene, 2000
Martin Sattler, Ravi Salgia
exaly  

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

Proceedings of the National Academy of Sciences of the United States of America, 2002
Charles L Sawyers, Richard A Van Etten
exaly  

Clinical management of gastrointestinal stromal tumors: Before and after STI-571

Human Pathology, 2002
Ronald P Dematteo, Michael Charles Heinrich   +1 more
exaly  

C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival

Cellular Signalling, 2009
Vera C Maia, Alvaro Gutierrez-Uzquiza, Almudena Porras   +2 more
exaly  

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Science, 2000
Patricia Pellicena, W Todd Miller, John Kuriyan   +2 more
exaly  

Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D4–Receptor Antagonist

New England Journal of Medicine, 1991
exaly  

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells

Leukemia, 2001
exaly  

STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’

Leukemia, 2002
exaly  

CANCER RESEARCH: Why Some Leukemia Cells Resist STI-571

Science, 2001
exaly